Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance

BioNTech SE - ADRTrade
KraneShares CSI China Internet ETFTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs KraneShares CSI China Internet ETF — how do they compare? BioNTech SE - ADR trades at $89.96 (market cap $22.86B), while KraneShares CSI China Internet ETF trades at $27.23. Which is the better fit depends on your goals.

BNTXKWEB
Market Cap
$22.86B
Sector
HealthSector/Thematic
52-Week High
$119.34$42.94
52-Week Low
$83.89$23.63
Enterprise Value
$6.53B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.

The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.

KraneShares CSI China Internet ETF

KWEB trades at $26.23, down 0.57% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides exposure to Chinese internet and AI companies, benefiting from government support and AI-driven growth, though key financial ratios are unavailable. Recent news highlights China's push for tech self-reliance and strong export performance.

Outlook is mixed: AI expansion and attractive valuations offer upside, but geopolitical tensions and regulatory risks pose challenges. The stock's performance hinges on China's economic policies and global tech competition, requiring careful risk assessment for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About KraneShares CSI China Internet ETF

KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.

Read more on KWEB